Drug Induced Liver Injury
Effectivley predict DILI with novel models and testing strategies bridging the gap between pre-clinical and clinical research
Informa Life Sciences’ Drug Induced Liver Injury is the only DILI focused event in Europe bridging the gap between pre-clinical and clinical research. Developed though rigorous research with key academic and industry experts in hepatotoxicity; this programme has been specifically designed to provide you with a tailored package of knowledge to propel your DILI testing strategy to the next level. Attend this innovative event to participate in discussions on up-to-the-minute scientific and technological breakthroughs enabling you to develop the best DILI testing strategy for your AIs.
Brand new topics for 2010:
- Be the first to hear feedback from ISEAC on definitions of DILI
- Keep abreast of the most innovative thinking in liver biology to understand the potential stumbling blocks for your candidate
- Hear brand new testing strategies and tools to predict DILI pre-clinically and avoid investing in DILI causing compounds
- Learn about the latest screening assays being developed to prevent the entry and occurance of DILI causing compounds
- Understand the objective relationship between signs and symptoms and clinical prediction of DILI
- Understand how the regulatory landscape is developing surrounding the use of predictive tests for DILI with key presentations from the FDA, BfArM and the ILI SAFE-T consortium
Homepage speakers
Homepage speakers
John R. Foster
Senior Principal Pathologist
AstraZeneca Pharmaceuticals, UK
|
Guruprasad Aithal
NHS Co-Director
Nottingham Digestive Disease Centre
|
Weida Tong
Director, Centre for Toxicoinformatics
National Centre for Toxicological Research, FDA
|
Kevin Park
Director, MRC Centre for Drugh Safety Science
University of Liverpool, UK
|
Other key speakers include:
Ann K. Daly PhD, Professor of Pharmacogenetics, Newcastle University, UK
Simone Stahl, Associate Principal Scientist, AstraZeneca, UK
Colin Howes, Associate Research Fellow, Pfizer, UK
Christine M. Hunt, Clinical Safety Systems, GSK, USA
Klaus Olejniczak, Scientific Director, Federal Institute for Drugs and Medical Devices (BfArM), Germany
Michael Merz, Head Safety Networks, Novartis, Switzerland
Christoph Wandel, Safety Science Leader, F. Hoffmann - La Roche Ltd, Switzerland
Event Sponsor
Media Partners
Dates and Venues
29 Jun 2010 - 30 Jun 2010
Renaissance Zurich Hotel
Poll
Which method holds the most promise for predicting DILI pre-clinically?
Please select an answer
Our expert speaker panel is made up of representitives from:
- AstraZeneca
- University of Liverpool
- Pfizer
- GSK
- F. Hoffmann La Roche
- FDA
- BfArM
- Novartis
- Newcastle University
- Frounhofer Institute
- Duke University
- University of Surray
- MSD
Those who attended last year include:
Safety, Metabolomics, Toxicology, Functional validation, Genomics,
Pharmacology, QT, ECG studies, Cardiac Safety, Drug Safety, DMPK,
ADME, Pre-clinical Safety, Data Management and DILI
AND Specialists/Senior Scientists working in:
Drug Safety and Surveillance, Drug Metabolism, Pharmacokinetics,
Proteomics, Pharmacogenetics, Immunoglogy, Bioinformatics,
Pharmacovigilance, Toxicology, Genetics, Modelling and Simulation,
Clinical & Pre-Clinical Pharmacology, Automated Biotechnology,
Medical Science, Product Safety, Drug Development and Clinical
Research, Regulatory Affairs, Quality Assurance
Event Sponsor
Media Partners
Reviews
"Excellent talks and very interesting topics"
"Small but high quality event"
"An interesting idea to co-locate with live safety"
"Good meeting overall, correct pitch for inaugural meeting. I would like to see further DILI conferences"
"Diverse and interesting talks"
